Abstract: Methods and systems for allowing multiple devices to display and annotate (or modify) a video image are described, where a content renderer device displays a video image that is also displayed (or viewed) by one or more content viewer devices, which can both display and annotate (or modify) the same video image at the same time, and the content renderer selectively determines whether or not a GUI menu is displayed on its display screen. Annotation commands (e.g., screen touch data) on the viewer devices are captured, packaged and sent to the content renderer, which creates a combined modified video image having the annotations from the viewer devices, displays it to the renderer display and sends it to the viewer devices for display thereon.

Abstract: A thermoelectric power generator for converting thermal energy into electrical energy. The thermoelectric power generator includes a heat exchanger configured to extract thermal energy from an exhaust gas stream. The heat exchanger includes fins in contact with a boundary of the heat exchanger, where the fins are directly connected to a first set of thermoelectric modules. A second set of thermoelectric modules are directly connected to the boundary of the heat exchanger. The first and second sets of thermoelectric modules are configured to convert the thermal energy to electrical energy. By eliminating the metal wall that previously existed between the thermoelectric modules and the fins, the thermoelectric power generator improves the heat transfer between the exhaust gas and the thermoelectric modules, eliminates the thermal fatigue failures at the bond between the metal wall and the thermoelectric modules as well as allows for a higher density of thermoelectric modules.

Abstract: Provided herein are methods of treating B7-H1-expressing tumors comprising administering an effective amount of MEDI4736 or an antigen-binding fragment thereof.

Abstract: Sugar alcohol blends of galactitol and mannitol and compositions comprising such blends are disclosed as phase change materials (PCMs). A method of forming carbon nanotubes on a carbon substrate is described. Carbon substrates with carbon nanotubes, in particular, conformal layers of carbon nanotubes on carbon substrates, are also disclosed, as are methods of making and using these materials. Thermal storage units are also provided. The thermal storage units can comprise a heat exchange path through which a heat exchange medium flows, and a thermal storage medium in thermal contact with the heat exchange path.

Abstract: The present invention features methods of treating lung cancer (e.g., NSCLC) with an anti-PD-L1 antibody and tremelimumab in a subject identified as having a PD-L1 negative tumor.

Abstract: Methods and systems for allowing multiple devices to display and annotate (or modify) a video image are described, where a content renderer device displays a video image that is also displayed (or viewed) by one or more content viewer devices, which can both display and annotate (or modify) the same video image at the same time, and the content renderer selectively determines whether or not a GUI menu is displayed on its display screen. Annotation commands (e.g., screen touch data) on the viewer devices are captured, packaged and sent to the content renderer, which creates a combined modified video image having the annotations from the viewer devices, displays it to the renderer display and sends it to the viewer devices for display thereon.

Abstract: The present invention generally relates to stimuli-responsive drug carriers and methods for making. More specifically, the present invention relates to stimuli-responsive lidded particles that respond to a physiological stimulus and dissolve at a target site inside the body thereby releasing therapeutic agents. The present invention further relates to solid, drug-loaded particles that are made from biodegradable polymers. The present invention further relates to methods for fabricating lidded particles and particles for drug delivery.

Abstract: A method of synthesizing corrugated and nanoporous microspheres including the steps of synthesizing substantially smooth spherical microspheres, and controlled wet-etching of the substantially smooth spherical microspheres with a basic solution having a pH above 10.00 is provided. The microspheres can include, for example, silica microspheres or titania microspheres of various sized diameters of between 50 nm and 600 nm. The basic solution can include an aqueous potassium cyanide solution or an aqueous potassium hydroxide solution. Methods of using the corrugated and nanoporous microspheres described herein are also provided.

Abstract: A telescopic universal joint includes a first joint and a second joint. A sleeve is connected to the second joint. A sliding member includes one end connected to the first joint, and is slidably received in the sleeve. A resilient ring is snugly arranged around the sliding member, and stays in a tight contact with an inner surface of the sleeve, thereby creating a friction between the resilient ring and the inner surface and allowing the sliding member to be positioned at a desired position by the friction.

Abstract: The present invention relates to pharmaceutical compositions comprising virus-like particles (VLPs) of HPV, said VLPs adsorbed to an aluminum adjuvant, and an ISCOM-type adjuvant comprising a saponin, cholesterol, and a phospholipid. In preferred embodiments, the aluminum adjuvant comprises amorphous aluminum hydroxyphosphate sulfate. Another aspect of the invention provides multi-dose HPV vaccine formulations comprising HPV VLPs and an antimicrobial preservative selected from the group consisting of: m-cresol, phenol and benzyl alcohol. Also provided are methods of using the disclosed pharmaceutical compositions and formulations to induce an immune response against HPV in a human patient and to prevent HPV infection.

Abstract: A protein-phospholipid dispersion preparation in a drug delivery system is provided, in which the weight ratio of protein to phospholipid is 1:300-300:1 and the particle size is between 5 nm and 1000 nm. The preparation process of the said preparation contains the mixture of protein phase and phospholipid phase and the homogenization process. The said drug delivery system can be used in many different pharmaceutical agents.

Abstract: The present invention relates to pharmaceutical compositions comprising virus-like particles (VLPs) of HPV, said VLPs adsorbed to an aluminum adjuvant, and an ISCOM-type adjuvant comprising a saponin, cholesterol, and a phospholipid. In preferred embodiments, the aluminum adjuvant comprises amorphous aluminum hydroxyphosphate sulfate. Another aspect of the invention provides multi-dose HPV vaccine formulations comprising HPV VLPs and an antimicrobial preservative selected from the group consisting of: m-cresol, phenol and benzyl alcohol. Also provided are methods of using the disclosed pharmaceutical compositions and formulations to induce an immune response against HPV in a human patient and to prevent HPV infection.

Abstract: A composite emulsifier, contains two or more emulsifiers selected from phospholipid, PEG emulsifier and poloxamer-like substance, and may contain cryoprotectant. An emulsion prepared from the composite emulsifier and a preparation method of the emulsion.

Abstract: The selective growth of vertically aligned, highly dense carbon nanotube (CNT) arrays using a thermal catalytic chemical vapor deposition (CCVD) method via selection of the supporting layer where the thin catalyst layer is deposited on. A thin iron (Fe) catalyst deposited on a supporting layer of tantalum (Ta) yielded CCVD growth of the vertical dense CNT arrays. Cross-sectional transmission electron microscopy revealed a Vollmer-Weber mode of Fe island growth on Ta, with a small contact angle of the islands controlled by the relative surface energies of the supporting layer, the catalyst and their interface. The as-formed Fe island morphology promoted surface diffusion of carbon atoms seeding the growth of the CNTs from the catalyst surface.

Abstract: The present invention relates to pharmaceutical compositions comprising virus-like particles (VLPs) of HPV, said VLPs adsorbed to an aluminum adjuvant, and an ISCOM-type adjuvant comprising a saponin, cholesterol, and a phospholipid. In preferred embodiments, the aluminum adjuvant comprises amorphous aluminum hydroxyphosphate sulfate. Another aspect of the invention provides multi-dose HPV vaccine formulations comprising HPV VLPs and an antimicrobial preservative selected from the group consisting of: m-cresol, phenol and benzyl alcohol. Also provided are methods of using the disclosed pharmaceutical compositions and formulations to induce an immune response against HPV in a human patient and to prevent HPV infection.

Abstract: A method of synthesizing corrugated and nanoporous microspheres including the steps of synthesizing substantially smooth spherical microspheres, and controlled wet-etching of the substantially smooth spherical microspheres with a basic solution having a pH above 10.00 is provided. The microspheres can include, for example, silica microspheres or titania microspheres of various sized diameters of between 50 nm and 600 nm. The basic solution can include an aqueous potassium cyanide solution or an aqueous potassium hydroxide solution. Methods of using the corrugated and nanoporous microspheres described herein are also provided.

Abstract: The present invention provides a Malaria antigen-carrier conjugate, which comprises a carrier protein and a plurality of Plasmodium antigen polypeptides. Each of the antigen polypeptides is a wild-type antigen protein of Plasmodium or a derivative of the wild-type antigen protein, and each of the antigen polypeptides may be the same, or different. The plurality of Plasmodium antigen polypeptides are covalently linked to the carrier protein. The present invention further provides a vaccine against malaria, which comprises the conjugate absorbed on an aluminum adjuvant.

Abstract: The present invention relates to pharmaceutical compositions comprising virus-like particles (VLPs) of HPV, said VLPs adsorbed to an aluminum adjuvant, and an ISCOM-type adjuvant comprising a saponin, cholesterol, and a phospholipid. In preferred embodiments, the aluminum adjuvant comprises amorphous aluminum hydroxyphosphate sulfate. Another aspect of the invention provides multi-dose HPV vaccine formulations comprising HPV VLPs and an antimicrobial preservative selected from the group consisting of: m-cresol, phenol and benzyl alcohol. Also provided are methods of using the disclosed pharmaceutical compositions and formulations to induce an immune response against HPV in a human patient and to prevent HPV infection.

Abstract: The present invention generally relates to stimuli-responsive drug carriers and methods for making. More specifically, the present invention relates to stimuli-responsive lidded particles that respond to a physiological stimulus and dissolve at a target site inside the body thereby releasing therapeutic agents. The present invention further relates to solid, drug-loaded particles that are made from biodegradable polymers. The present invention further relates to methods for fabricating lidded particles and particles for drug delivery.

Abstract: An augmented reality system with mobile and interactive functions for multiple users includes two major portions: a computer system for handling augmented reality functions, and a user system for each user. The computer system for handling augmented reality functions has very powerful functionality for processing digital image data and transforming the digital image data into a three-dimensional virtual image for each user system. The user system mainly includes a Head-Mounted Display (HMD), a microphone and a PDA. A user can see the virtual image from the HMD and use the microphone or the PDA for communication with other users.